You've just added:

April 12, 2022

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19

Entry of the SARS-CoV-2 coronavirus, which causes COVID-19, requires a host serine protease called TMPRSS2. Camostat mesylate, an orally available serine protease inhibitor, inhibits TMPRSS2, supporting clinical trials to investigate its use in COVID-19.

"The use of innovative modeling by Harrington gave us new insights into how to use Camostat clinically."

- Joseph Vinetz, MD

Click here to read the full article in Microbiology Spectrum

About the Scholar

Joseph Vinetz

Infectious Disease, Virology

Joseph Vinetz, MD

Yale University
2020 Harrington Award for Coronavirus

More about Joseph Vinetz